Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma

Oncology

Volumn 81, Issue 3-4, 2011, Pages 184-191

  Kim, Do Young ^a,b   Ahn, Sang Hoon ^a,b   Kim, Seung Up ^a,b   Choi, Sae Byeol ^b   Lee, Kwang Hun ^a,b   Park, Mi Sook ^a,b   Park, Jun Yong ^a,b   Lee, Do Yun ^a,b   Han, Kwang Hyub ^a,b   Kim, Kyung Sik ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

Adjuvant therapy; Hepatic arterial infusional chemotherapy; Hepatocellular carcinoma

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84255170904     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000333827     Document Type: Article

References (27)

1. Shimada M, Takenaka K, Gion T, et al: Prognosis of recurrent hepatocellular carcinoma: A 10-year surgical experience in Japan. Gastroenterology 1996; 111: 720-726.
2. Hsu HC, Sheu JC, Lin YH, et al: Prognostic histologic features of resected small hepatocellular carcinoma (HCC) in Taiwan, a comparison with resected large HCC. Cancer 1985; 56: 672-680.
3. Ikeda K, Saitoh S, Tsubota A, et al: Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. Cancer 1993; 71: 19-25.
4. Poon RT, Fan ST, Ng IO, et al: Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000; 89: 500-507.
5. Sugimoto R, Okuda K, Tanaka M, et al: Metachronous multicentric occurrence of hepatocellular carcinoma after surgical treatment- clinicopathological comparison with recurrence due to metastasis. Oncol Rep 1999; 6: 1303-1308.
6. Ando E, Yamashita F, Tanaka M, et al: A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer 1997; 79: 1890-1896.
7. Epirubicin Study Group for Hepatocellular Carcinoma: Intra-arterial administration of epirubicin in the treatment of nonresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 1987; 19: 183-189.
8. Itamoto T, Nakahara H, Tashiro H, et al: Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. J Surg Oncol 2002; 80: 143-148.
9. Park JY, Ahn SH, Yoon YJ, et al: Repetitive short-course hepatic arterial infusional chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007; 110: 129-137.
10. Hanazaki K, Matsushita A, Nakagawa K, et al: Risk factors of long-term survival and recurrence after curative resection of hepatocellular carcinoma. Hepatogastroenterology 2005; 52: 552-557.
11. Takayama T, Sekine T, Makuuchi M, et al: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomized trial. Lancet 2000; 356: 802-807.
12. Tang ZY, Yu YQ, Zhou XD, et al: Progress and prospects in hepatocellular carcinoma surgery. Ann Chir 1998; 52: 58-563.
13. Lee JG, Kang CM, Park JS, et al: The actual five-year survival rate of hepatocellular carcinoma patients after curative resection. Yonsei Med J 2006; 47: 105-112.
14. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
15. Nelson RS, de Elzalde R, Howe CD: Clinical aspects of primary carcinoma of the liver. Cancer 1996; 19: 533-537.
16. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
17. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
18. Nagamatsu H, Hiraki M, Mizukami N, et al: Intra-arterial therapy with cisplatin suspension in lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis. Aliment Pharmacol Ther 2010; 32: 543-550.
19. Ueshima K, Kudo M, Takita M, et al: Hepatic arterial infusion chemotherapy using lowdose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology 2010; 78(suppl 1):148-153.
20. Kim BK, Park JY, Choi HJ, et al: Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2011; 137: 659-667.
21. Izumi R, Shimizu K, Iyobe T, et al: Postoperative adjuvant hepatic arterial infusion of lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology 1994; 20: 295-301.
22. Ueno S, Tanabe G, Yoshida A, et al: Postoperative prediction of and strategy for metastatic recurrent hepatocellular carcinoma according to histologic activity of hepatitis. Cancer 1999; 86: 248-254.
23. Kumada T, Nakano S, Takeda I, et al: Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997; 25: 87-92.
24. Sakon M, Umeshita K, Nagano H, et al: Clinical significance of hepatic resection in hepatocellular carcinoma: Analysis by diseasefree survival curves. Arch Surg 2000; 135: 1456-1459.
25. Kohno H, Nagasue N, Hayashi T, et al: Postoperative adjuvant chemotherapy after radical hepatic resection for hepatocellular carcinoma (HCC). Hepatogastroenterology 1996; 43: 1405-1409.
26. Lai EC, Lo CM, Fan ST, et al: Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: A randomized controlled trial. Arch Surg 1998; 133: 183-188.
27. Kelsen D: Preoperative chemoradiotherapy for esophageal cancer. J Clin Oncol 2001; 19: 283-285.